Prepare for your visit

Alan M Siegal

Endocrinology, Diabetes & Metabolism · Birmingham, AL · NPI 1760531511

One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.

What was reported

$112.44

in general payments reported to CMS, 2019-2025 · $20.99 in 2025

The $20.99 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).

Who reported paying

General payments only, top 3 by amount.

Novartis Pharmaceuticals Corporation $72.90
Otsuka America Pharmaceutical, INC. $20.99
Allergan, INC. $18.55

Drugs and devices associated with these payments

Rexulti

Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.

Questions you might ask

I saw Alan Siegal listed in the CMS Open Payments database. Can you tell me about your work with those companies?
Is there a generic or alternative to this medication, and would it work as well for me?
What made you choose this particular treatment for my situation?

These are normal questions. A good clinician will welcome them.

Notes

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.

GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/1096848/alan-m-siegal